Concert Pharma (CNCE) Reports Q4 Loss of $0.69/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailGet Alerts CNCE Hot Sheet
Join SI Premium – FREE
Concert Pharma (NASDAQ: CNCE) reported Q4 EPS of ($0.69), versus $0.86 reported last year.
For earnings history and earnings-related data on Concert Pharma (CNCE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Takeda Pharmaceutical Company Limited (TAK) Reports Q3 EPS of JPY308.00; offers guidance
- California Water Service (CWT) Misses Q3 EPS by 11c
- Bank of Princeton (BPRN) Misses Q3 EPS by 80c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
